Phelan-McDermid syndrome or 22q13.3 deletion syndrome is a rare neurodevelopmental disorder characterized by generalized developmental delay, intellectual disability, absent or delayed speech, seizures, autism spectrum disorder, neonatal hypotonia, physical dysmorphic features, and recurrent medical comorbidities. Individuals with Phelan-McDermid syndrome have terminal deletions of the chromosomal region 22q13.3 encompassing SHANK3, a gene encoding a structural component of excitatory synapses indispensable for proper synaptogenesis and neuronal physiology, or point mutations within the gene. Here, we review the clinical aspects of the syndrome and the genetic findings shedding light onto the underlying etiology. We also provide an overview on the evidence from genetic studies and mouse models that supports SHANK3 haploinsufficiency as a major contributor of the neurobehavioral manifestations of Phelan-McDermid syndrome. Finally, we discuss how all these discoveries are uncovering the pathophysiology of Phelan-McDermid syndrome and are being translated into clinical trials for novel therapeutics ameliorating the core symptoms of the disorder.
gastroesophageal reflux, lymphedema, and strabismus. 5 To date, several studies have also implied that subjects with Phelan-McDermid syndrome are at a higher risk to develop atypical bipolar disorder [12] [13] [14] and show progressive loss of skills during their lifetime. Prominent neurologic regression during aging and even death in early and mid adulthood has been also reported in Phelan-McDermid syndrome. [15] [16] [17] The Etiology Underlying Phelan McDermid Syndrome Phelan- McDermid syndrome is frequently caused by the loss of the distal segment of the long arm of chromosome 22, as the consequence of terminal or interstitial (subtelomeric) deletions, balanced or unbalanced translocations, ring chromosomes (the chromosome arms are fused together to form a ring), and mosaicisms of these anomalies, and, as will be discussed below, SHANK3 mutations. [3] [4] [5] [6] 15, 16, [18] [19] [20] [21] [22] [23] [24] [25] [26] Microscopically visible rearrangements, including large deletions, translocations, and ring chromosomes, can be detected with G-banding karyotyping, 5, 16 whereas cryptic translocations can be revealed using fluorescence in situ hybridization. 27 Microarray technologies, including array-based comparative genomic hybridization and chromosome microarray analysis, as well as targeted deletion analysis by fluorescence in situ hybridization or multiplex ligation-dependent probe amplification, are efficient in capturing submicroscopic deletions. 5, 6, 16, 19 Sequencing technologies are expanding the landscape of Phelan-McDermid syndrome etiology to intragenic variation, including point mutations. Because Phelan-McDermid syndrome can be misdiagnosed with other disorders, 3 the technological advances and integration of cytogenetic and molecular genetic techniques are essential to enable earlier and more accurate diagnosis. For example, individuals diagnosed with nonsyndromic autism spectrum disorder can be found with 22q13.3 deletions, as revealed by screenings of autism spectrum disorder cohorts using fluorescence in situ hybridization, 15 microarrays, 23, 25, [28] [29] [30] [31] [32] [33] [34] or analysis of copy number variation from whole-exome sequencing data. 26, 35 About 75% of Phelan-McDermid syndrome subjects have terminal deletions that in most cases are de novo and paternally derived. 4, 6, 16, 20 Terminal deletions have typically nonrecurrent breakpoints and can extend up to 9 Mb. 4, 5, 16 Studies on genotype-phenotype correlations have converged on an association between the size of the deleted region and the number and/or severity of clinical manifestations, [4] [5] [6] [7] 20, 36 although the specific findings on phenotypic variables are not completely consistent across studies. A report on 30 individuals carrying ring 22 chromosome found that the deletion size correlated with certain dysmorphic features and with the severity of developmental and speech delay. 18 Another study on 56 individuals with terminal deletions found that the deletion size was associated with developmental delay, hypotonia, head circumference, recurrent ear infection, pointed chin, and dental anomalies. 20 Analyses from three nonindependent Phelan-McDermid syndrome cohorts (the extended cohort comprises 201 participants 4 ) have shown that developmental delay, abnormal growth, and dysmorphic features are more pronounced in carriers of larger deletions, with macrocephaly and speech ability being the more robust associations. 4, 7, 36 Conversely, aggressive behavior and autism spectrum disorder (assessed using parent report) are inversely correlated with deletion size. 4, 7, 36 An investigation of 32 subjects has noted a significant correlation between deletion size and number of dysmorphic features or medical comorbidities. 5 In contrast with the results from Sarasua and colleagues, no changes were found in speech ability. Also, two standard autism spectrum disorder diagnostic scores related to social interactions and communication were positively correlated with deletion size. 5 These results indicate that the autism spectrum disorder behavioral manifestations exacerbate with increasing deletion size.
The evidence that the penetrance and expressivity of the symptoms correlate with the extent of the deleted region suggests that more than one haploinsufficient gene contributes to Phelan-McDermid syndrome phenotype. Amongst the 90 genes that can be deleted as a consequence of the 22q13.3 rearrangements, SHANK3, one of the 3 genes lost in all terminal deletions, 6 has emerged as the most robust candidate gene for the neurobehavioral correlates of Phelan-McDermid syndrome. First of all, many subtelomeric deletions 16, 37, 38 or translocations 27 have their breakpoints in SHANK3. In the first report, the authors described a de novo reciprocal balanced translocation between chromosomes 12 and 22 with the breakpoint in exon 21 of SHANK3 in a child exhibiting the typical facial dysmorphic features, mild hypotonia, dolichocephaly, mild intellectual disability and severe speech impairment. 27 Only 12 individuals with interstitial deletions not involving SHANK3 have been reported thus far. 39, 40 These patients display a phenotype partially overlapping with Phelan-McDermid syndrome, including developmental delay, hypotonia, overgrowth, and macrocephaly. 39, 40 However, the autism spectrum disorder symptomatology has not exhaustively been described in these patients: autism spectrum disorder was assessed only in 3 patients out of 12, among which 2 were reported as being affected. 40 It is noteworthy to mention that none of the symptoms of Phelan-McDermid syndrome is unique for the syndrome. In fact, other large chromosomal rearrangements result in a similar array of symptoms.
Another line of evidence supporting that SHANK3 haploinsufficiency is the major determinant of the neurobehavioral symptoms relates to the discovery of SHANK3 point mutations in subjects with phenotypes overlapping Phelan-McDermid syndrome and autism spectrum disorder. Among the 32 subjects examined by Soorya and colleagues, two carry de novo mutations (a nonsense and a frameshift mutation) and show core features of Phelan-McDermid syndrome. 5 The subject with a de novo frameshift mutation (p.R834RfsX59) displays dolichocephaly and short stature, hypotonia, intellectual disability, repetitive behavior, hyperactivity, aggression, seizures, but no autism spectrum disorder. 5 The subject with a de novo nonsense mutation (p.W509X) has several dysmorphic features, macrocephaly, intellectual disability, repetitive behavior, hyperactivity, and autism. 5 Furthermore, large-scale targeted resequencing 15, [22] [23] [24] [25] and whole-exome sequencing 26 have identified SHANK3 point mutations or indels in subjects diagnosed with autism spectrum disorder. Some of these patients retrospectively present with manifestations of Phelan-McDermid syndrome, although with a certain degree of variability. 25 It is also worth mentioning that the contribution of point mutations/indels is likely underestimated by the current studies: the identification of variants in SHANK3 has been hindered by the poor coverage of whole-exome sequencing because of the high CG content of this gene 8, 20, 41 ; therefore, targeted resequencing has been the most effective approach. Finally, the genetic evidence pinpointing SHANK3 as a major determinant in Phelan-McDermid syndrome phenotype is coalescing with findings from cell and mouse models, as we shall further discuss below. Briefly, mice deficient or ablated for Shank3 show an array of neuroanatomical, physiological, and behavioral phenotypes that are consistent with the clinical manifestations of Phelan-McDermid syndrome. [42] [43] [44] [45] [46] Also, some of the physiological defects observed in functional neurons differentiated from induced pluripotent stem cells derived from individuals with Phelan-McDermid syndrome can be alleviated by reintroducing SHANK3. 47 All together, these findings indicate that SHANK3 haploinsufficiency is sufficient to lead to Phelan-McDermid syndrome.
In addition, there are observations implicating 22q13.3 and/ or SHANK3 perturbations in other disorders. Five subjects have been reported with 22q13.3 duplications and other psychiatric conditions (Asperger syndrome, 15 attention-deficit hyperactivity disorder [ADHD], 23 schizophrenia, 48 and hyperkinetics disturbances 49 ). Furthermore, de novo SHANK3 mutations have been detected in individuals diagnosed with atypical schizophrenia 50 or intellectual disability. 51, 52 Finally, mutations or copy number variants in other genes of the SHANK family (SHANK1 and SHANK2) have been described in cases of autism spectrum disorder and intellectual disability. 25, 30, [53] [54] [55] The Shank Family Each of the SHANK1, SHANK2, and SHANK3 genes is positioned on a different chromosomal location and encode for the Shank1, Shank2, and Shank3 proteins, respectively. These genes are part of a family of proteins known by different names, that is, the Shank protein family, the proline-rich synapse-associated proteins (ProSAP), 56 the cortactin-binding proteins (CortBP), 57 the somatostatin receptor interacting proteins (SSTRIP), 58 or the synamons. 59 This family of proteins is highly enriched in a specific compartment of the postsynaptic membrane of excitatory synapses, known as the postsynaptic density (PSD). 60 The PSD is an ultrastructural thickening that is composed of a network of scaffolding proteins, among which the Shank molecules represent about 5% of the total protein molecules and total protein mass. 61 Each of the Shank encoding genes contains numerous splicing sites and alternative promoters, thus producing several isoforms, 44, 56, 58, 59, 62 which contribute to the transcriptional and functional complexity that these genes deliver. 63 Shank members are expressed in the peripheral organs as well as in the brain. Within the brain, they were all shown to be expressed in the cortex and hippocampus, whereas Shank1 expression was also detected in the amygdala, substantia nigra, and thalamus and Shank2 expression was detected in the olfactory bulb and the central gray matter. High levels of Shank3 were detected in the striatum. 64 In the cerebellum, Shank2 and Shank3 are differentially expressed in the Purkinje and the granule cells, respectively. 56, 65 This differential expression could be mediated by epigenetic modifications including DNA methylation, which was previously shown to regulate tissue-specific expression of Shank3. [66] [67] [68] A full-length Shank isoform harbors 5 protein-protein interaction motifs/domains: the ankyrin repeats domain (ANK), an Src homology 3 (SH3) domain, a PDZ domain, a proline-rich region, and a sterile a-motif (SAM) domain. 65, 69 Through the SAM domain, the Shank proteins can self-assemble to form the Shank platform at the PSD, which plays a vital role in synaptogenesis and synaptic maintenance and plasticity. [70] [71] [72] Through the other domains, Shank proteins can also form direct and indirect interaction with additional scaffolding proteins within the PSD, with the glutamatergic receptors (a-amino-3hydroxy-5-methyl-4-isoxazoleproprionic acid [AMPA] and N-methyl-D-aspartate [NMDA] receptors) and cell adhesion molecules at the membrane, and with cytoskeletal components within the post-synapse. 65, 73, 74 Because they have an essential role in structuring and organizing the PSD, Shank proteins shape the synaptic morphology and function; thus, perturbations of their expression profoundly affect synaptic composition and physiology. 71, [75] [76] [77] [78] [79] [80] For example, Shank1 or Shank3 overexpression in hippocampal cultures increased the levels of polymerized actin (F-actin) in dendritic spines and promoted their maturation, 75, 79 whereas Shank1 silencing affected both spine size and number, and led to reduced PSD thickness. 76 Moreover, altering Shank2 and Shank3 levels by manipulating the Zn 2þ extracellular concentration led to changes in the PSD size and affected the assembly of the immature synapse. 61, 71 Finally, expression of Shank3 into aspiny cerebellar neurons provoked the maturation of spines with functional excitatory synapses. 77 Changes in synaptogenesis and spine morphology induced by Shank proteins mirror effects on neuronal activity, including AMPARand NMDAR-mediated synaptic transmission, transsynaptic transmission, and synaptic plasticity. [75] [76] [77] [78] [79] Furthermore, the neuronal effects of 22q13.3 deletions have recently been studied in human neurons differentiated from induced pluripotent stem cells derived from two individuals with Phelan-McDermid syndrome. 47 Compared with control neurons, Phelan-McDermid syndrome neurons showed deficits in excitatory, but not inhibitory, synaptic transmission, fewer excitatory synapses, and decreased expression of excitatory neurotransmitter receptors. The alterations in synaptic transmission could be reversed by restoring SHANK3 expression. 47 De novo and inherited SHANK3 mutations have been found in individuals with autism spectrum disorder. 15, 23 By transfecting wild-type and mutant SHANK3 in primary hippocampal neurons, independent studies have found that 3 of the reported point mutations (p.R12C, p.R300C, p.Q321R, the latter 2 in the ANK domain) do not interfere with the postsynaptic targeting, but affect the number and the morphology of dendritic spines, synaptic F-actin levels, and spontaneous neuronal activity. 78, 79, 81 Furthermore, a prematurely truncated SHANK3 resulting from a frameshift mutation in exon 21 15 and missing the SAM domains and the binding sites for critical partners (Homer and Cortactin) was retained in the soma when overexpressed in hippocampal neurons. The truncated SHANK3 also exerts a dominantnegative effect on spine induction and synaptic transmission. 78, 79 Another missense mutation (p.L68P) 24 located in the N-terminal domain does not compromise postsynaptic targeting or synaptic transmission, but enhances the interaction with cytoskeletal components. 81 The 2 mutations identified by Soorya and colleagues are also being tested for their impact on synaptic localization, neuronal morphology, and synapse formation. 82 To further clarify the function and the role of the Shank proteins in the brain, several groups have developed and characterized genetically modified mice models with deficiency in one of the Shank family members, aiming to mimic some of the aforementioned human mutations.
Animal Models for Shank Genes Deficiency
Animal models are advantageous for understanding the function of genes and their encoded proteins in the context of the entire organism. In addition to their particular value in investigating the complex interplay of molecular and cellular pathways within the brain, they are preferable models for studying neurodevelopmental disorders where behavioral deficits are among the core symptoms. Given the relevance for SHANK1 and SHANK2 mutations in autism spectrum disorder, we will briefly report on the findings in animal models mimicking their deficiency. We will provide a more extended summary of the available Shank3-deficient mice models, which are being used as a mean for understanding the pathophysiology of Phelan-McDermid syndrome and autism spectrum disorder and for the discovery of new therapeutic targets.
Shank1-Deficient Mice
Shank1-deficient mice were the first to be generated to study the function of the Shank proteins in vivo. 76 In this model, Shank1 is lacking most of the PDZ domain leading to undetectable levels of the protein. The mice show altered PSD protein composition, reduced dendritic spine size, smaller and thinner PSDs, and reduced basal synaptic transmission with no change in synaptic plasticity. Behaviorally, the mice have anxiety, impaired motor learning and contextual fear memory, and enhanced performance in spatial learning but impaired longterm memory retention in the same task. They do not show any autism-relevant social interaction deficits. 83 However, they display deficits in the emission of ultrasonic vocalizations in the pups and urine-based communicative behaviors in the adult males, indicating a specific deficit in social communicative behavior, 84 and alterations in self-grooming and marble burying behaviors, reflecting changes in their repetitive behavior. 85
Shank2-Deficient Mice
Several mutations and small deletions in SHANK2 have been reported in subjects with autism spectrum disorder. 55 Functional studies on 3 mutations found in patients (p.L1008_P1009dup, p.T1127M, p.R462X) have shown that overexpression of mutant SHANK2 proteins lead to smaller spines, fewer synapses, and more complex dendritic branches, and that one mutation (p.R462X) causes mislocalization. Furthermore, newborn mice were injected with viral particles carrying Shank2-R462X. Electrophysiological recordings of the hippocampal slices isolated 3 months after the injection showed reduction in miniature postsynaptic AMPA receptor currents (Berkel et al, 2012) . 86 Also, Shank2-R462X expressing mice were less likely to investigate a novel object and less capable at navigating a maze than control mice (Berkel et al, 2012) . 86 Following these studies, 2 Shank2-deficient mice models were generated by targeting the PDZ domain of Shank2. The first model harbors a deletion of exons 6 and 7 (Shank2 -/-, ex6-7 ), 87 whereas the second one has a deletion spanning exon 7 (Shank2 -/-, ex7 ). 88 Using different social behavior paradigms, both models showed impaired social behaviors, altered social communication assessed as ultrasonic vocalizations, and stereotypies, measured as grooming and digging behavior. The Shank2 -/-, ex6-7 model was further challenged on the Morris water maze to examine the cognitive functioning; using this task, mice displayed impaired spatial learning, but no deficits in working memory, object recognition memory, or motor learning. Despite the similar behavioral phenotype of both models, findings related to synaptic physiology showed some discrepancies. While Schmeisser and colleagues reported an increase in NMDAR-mediated synaptic function in the Shank2 -/-, ex7 model, 88 Won and colleagues reported an opposite observation. 87
Shank3-Deficient Mice
To investigate the pathophysiological consequences of SHANK3 haploinsufficiency, pinpoint one or more nexus for therapeutic intervention, and establish animal models for drug testing, four independent groups have generated murine lines mimicking Shank3 deficiency or ablation. 42, 44, 45, 64 Also, given the clinical relevance of SHANK3 duplications, 15,23,48 a Shank3-overexpressing mouse model recapitulating hyperkinetic disorder has been generated. 49 In the first published model of Shank3 deficiency, the targeted region spans exons 4-9 (encoding the ANK domain), a region of clinical relevance since it can harbor mutations detected in subjects with autism spectrum disorder and intellectual disability. 23, 89 Exons 4-9 excision disrupted the full-length Shank3 isoform (Shank3a). 42 Mice heterozygous for exons 4-9 deletion have a significant reduction in basal glutamatergic synaptic transmission in the hippocampus, specifically in the component mediated by the AMPA receptors (AMPAR), as compared with wild-type littermates. 42 Such effect is likely due to a decrease in synaptic AMPARs, because neurons from Shank3 heterozygous animals have an attenuated expression of the AMPAR subunit GluR1. In addition to basal transmission, Shank3 deficiency caused defects in synaptic plasticity, with robust deficits in the maintenance of long-term potentiation but no perturbations in long-term depression. The lack of stabilization of the synaptic potentiation was accompanied by a transient enlargement of the dendritic spine volume, which was in contrast persistent in control animals. The authors hypothesized that the deficits in synaptic consolidation could be due to altered AMPA receptor trafficking. Behavioral analyses also indicated that Shank3 heterozygotes had deficits in reciprocal social interaction and communication, as documented by reduced social sniffing and ultrasonic vocalizations during interactions between males and estrus females. These analyses and other behavioral tests were performed on two additional experimental cohorts to obtain a comprehensive phenotyping of Shank3 heterozygous and homozygous mice at infant, juvenile, and adult ages. 43 The larger study confirmed previous data on impaired AMPA-mediated basal transmission and long-term potentiation maintenance, and extended these findings to homozygous animals. The electrophysiology data were also corroborated by a subsequent study on the same model. 90 However, behavioral testing on the 3 cohorts revealed variability across animal cohorts. 43 Overall, Shank3 mutant mice displayed mild behavioral deficits, including reduction in some measures of juvenile reciprocal social interactions, higher levels of repetitive self-grooming, and impaired motor learning. 43 The model generated by Bozdagi and colleagues was also screened for strain-specific effects on behavioral performances. 42 Negligible strain effects were observed when comparing the behaviors of heterozygous or homozygous mice across genetic backgrounds, 46 indicating that behavioral phenotypes associated with Shank3 haploinsufficiency are largely strain-independent.
Using the same approach of Bozdagi et al, 42 an independent group generated a homozygous model targeting exons 4-9 and suppressing Shank3a expression (Shank3 ex4-9 model). 44 Shan-k3 ex4-9 mice showed abnormal social behavior (reduced preference for social interaction, decreased social initiation, excessive self-grooming) and deficits in social communication (altered ultrasonic vocalizations). Mutant mice also displayed modest learning impairments as measured in the water maze test, obsessive behaviors, and mild motor deficits with tests in vertical placement, climbing down a vertical pole, footmisplacement tasks, and accelerating rotarod. On the neuroanatomical side, an increase in the density of dendritic spines and significantly longer spines (resembling an immature phenotype) were noted in 4 weeks old but not 10 weeks old Shan-k3 ex4-9 mice. In line with earlier findings from Bozdagi and colleagues, 42 the mutant mice displayed reduced hippocampal long-term potentiation, and the AMPA receptor subunit GluR1 showed reduced surface expression upon induction of longterm potentiation. Unlike previous observations, 42 basal transmission function was intact.
Two more Shank3 murine models were generated and characterized by Peca and colleagues. 64 In the first line (Shank3A -/-), exons 4-7 (ANK domain) were targeted, causing the ablation of the full-length Shank3a, with no perturbations of the Shank3b and Shank3g isoforms. In the second line (Shank3B -/-), exons 13-16 (PDZ domain) were deleted; as a consequence, Shank3a and Shank3b were fully suppressed, whereas Shank3g was significantly downregulated. Shank3A -/mice showed little to no behavioral alterations when compared with controls. Conversely, Shank3B -/mice developed excessive grooming, anxiety-like behavior, and substantial deficits in social interaction, including perturbed social interactions and impaired recognition of social novelty. These behavioral anomalies were mirrored by biochemical, anatomical, and electrophysiological changes in the striatum. The expression of several scaffolding proteins, including SAPAP3, Homer1, PSD93, and the glutamate receptors subunits GluR2, NR2A and NR2B, was reduced in PSD preparations isolated from the striatum of Shank3B -/mice. Also, the striatum of the mutant mice was hypertrophic, and the striatal medium spiny neurons had more complex dendritic arborization with reduced dendritic spine density. The dendritic spines had no alterations in morphology, but exhibited thinner and shorter PSDs. Electrophysiological recordings indicated perturbed corticostriatal circuitry function in these mice, likely due to a loss in the number of functional synapses on the striatal medium spiny neurons and decreased postsynaptic responses from these synapses. In contrast with other observations, 42, 43 no changes were detected while recording the hippocampal synaptic transmission.
Another mouse model was generated by deleting exon 21 (Shank3 DC/DC ), which encodes the Homer binding domain, resulting in the loss of all the major isoforms detectable by Western blot. 45 The design was based on two clinical reports implicating exon 21: one subject with Phelan-McDermid syndrome and a balanced translocation having a breakpoint within exon 21, 27 and another individual diagnosed with autism spectrum disorder carrying a disrupting frameshift in this exon. 15 Shank3 DC/DC mice showed no global changes in the PSD proteins in hippocampal total lysates and purified synapses (synaptosomes), whereas the synaptic expression of the metabotropic glutamate receptor mGluR5 was elevated. Furthermore, Shank3 DC/DC animals had impaired spatial learning, poor motor coordination, avoidance toward inanimate objects, and excessive self-grooming in advanced adulthood. No alterations in ultrasonic vocalizations were observed. The neuronal morphology appeared unaltered in the mutant mice, with no differences in spine density and shape when compared with control littermates. Electrophysiological recordings on hippocampal slices indicated impaired long-term potentiation, but no changes in mGluR-dependent long-term depression, despite the observed increase in mGluR5. 45 The comparison of these studies highlight discrepancies in many of the domains explored, and isoform specificity might account for some of the differences observed. Alterations in the biochemical composition of the PSD were found in the striatum of the Shank3B -/model, 64 in the hippocampus of Shank3 e4-9 homozygous mice, 44 but not in the hippocampus of Shank3 DC/DC mice. 45 Spine density and morphology were found abnormal in striatal medium spiny neurons of Shank3B -/animals 64 and hippocampal neurons of Shank3 e4-9 homozygous mice 44 but not Shank3 DC/DC mice. 45 Basal glutamatergic synaptic transmission in the hippocampus was intact in Shank3 e4-9 homozygous mice, 44 altered as a result of AMPAR-mediated transmission in the independent model with the same deletion, 42, 43 or altered as a consequence of NMDARmediated transmission in the Shank3 DC/DC animals. 45 All the studies converge on a decrease in long-term potentiation but not in long-term depression. [42] [43] [44] [45] 90 Grooming was excessive in Shank3B -/but not in Shank3A -/animals 64 ; in Shank3 DC/DC , but only in old animals 45 ; and in male Shank3 heterozygous mice, a trend was reported. 43, 46 Motor impairments assessed with different paradigms were reported in some studies [43] [44] [45] 90 but not others. 46 Anxiety levels were found normal, 43 increased, 64 or decreased. 46 Variability across studies affects social interactions and social communication, two core features for autism spectrum disorder. Social interactions were found consistently affected in freely interacting animal pairs. 44, 64 In three-chamber arenas, mutant models showed higher preference for the interactions with the object rather than the social partner in a study 64 but not in other models, 43, 45, 46 along with reduced interest for social novelty in two models 45, 64 but not others. 46 As for social communication, emission of ultrasonic vocalizations was found affected in some models and cohorts [42] [43] [44] but not in others. 45 The discrepancies discussed above illustrate how difficult it is to draw a unifying phenotype when dealing with different models. Yet, the convergences across models indicate that Shank3 knockdown or knockout affect synaptic structure and function, forms of synaptic plasticity, and autism-related behaviors. Also, the results of these studies emphasize the importance of comparing phenotypes at all scales (biochemical, neuroanatomical, electrophysiological, and behavioral) across experimental designs. 91 This is of utmost importance for Phelan-McDermid syndrome, given its phenotypic complexity and the relevance for these animal models to help disentangling the contribution of SHANK3 from other potentially haploinsufficient genes in the 22q13.3 deleted region.
Behavioral and Therapeutic Interventions in Phelan-McDermid Syndrome
Given the phenotypic heterogeneity, there is no generalized intervention that applies to all cases of Phelan-McDermid syndrome, and no pharmacological treatments are currently available to target the underlying pathophysiology of the disorder. Treatment strategies are tailored to the patient after a thorough medical history and physical examination to identify the clinical manifestations, so that each symptom and comorbidity can be addressed specifically, usually with approaches or medications adopted and adapted from those applied in the general population. For example, early intervention programs and intensive physical and occupational therapies are recommended for motor skill deficits; appropriate medication is prescribed for hyperactivity, anxiety, and self-stimulatory behaviors; and cardiac, renal, respiratory and other conditions are managed using standard protocols (see Phelan and McDermid 3 and Kolevzon et al 92 for further discussion). If autism spectrum disorder is ascertained in Phelan-McDermid syndrome, behavioral and psychological treatments are considered as a first line of intervention. The aim for such treatments is to shift the trajectory of the child's atypical development toward a more typical developmental path. [93] [94] [95] Clearly, none of the aforementioned treatments addresses the core symptoms or targets the core deficits at the molecular, cellular, or circuitry level. Therefore, there is still an urgent need to develop pharmacologic treatments that address the bases of the disorder. Here is where animal models for Phelan-McDermid syndrome are extremely valuable. A thorough analysis of these models allows us to understand the basic neurobiology of SHANK3, and to reveal mechanisms or pathways that are affected by Shank3 deficiency. Once identified, components of these pathways can be targeted pharmacologically to reverse the deficits at the physiological and behavioral level. This translational approach has been recently applied in monogenic disorders associated with autism spectrum disorder, including Fragile X syndrome, tuberous sclerosis, Rett syndrome, neurofibromatosis, [96] [97] [98] and based on our work in rodents, 90 Phelan-McDermid syndrome. 99 For instance, basic studies on animal models for Fragile X syndrome have pointed to excessive mGluR5 signaling as a major determinant of the pathology. 96 Therefore, studies in preclinical models have shown the efficacy of mGluR5 antagonists or allosteric modulators in reversing the core deficits associated to the syndrome, and these findings have been brought into clinical trials. [100] [101] [102] [103] A similar approach is being used for therapeutic candidates targeting the GABAergic system, which has also been found altered in Fragile X. 104 Another example evolves from studies on mouse models for tuberous sclerosis, which indicate that mTOR signaling is excessively activated, contributing to the neuropsychiatric phenotypes, including cognitive deficits. 105 Therefore, mTOR inhibitors were tested in these models for their ability to reverse the observed phenotypes and were found to have a beneficial effect on the cognitive function and the neurological symptoms, even if treatment was initiated in adult animals. 97 As in the case of Fragile X syndrome, these findings are being translated into clinical trials. 106 In Phelan-McDermid syndrome, our study on Shank3 heterozygous mice showed beneficial effects of IGF-1 treatment in reversing synaptic and motor deficits, 90 and an independent study has found that IGF-1 is effective in reversing the synaptic deficits observed in neurons derived from induced pluripotent stem cells of patients with Phelan-McDermid syndrome. 47 These preclinical findings have led to a first pilot clinical trial with IGF-1 in Phelan-McDermid syndrome, which has shown benefits with IGF-1 on core symptoms of autism spectrum disorder, suggesting a potentially disease-modifying effect, and forming the basis for larger studies to inform the efficacy of IGF-1 in Phelan-McDermid syndrome. 99 Notably, independent clinical studies on IGF-1 in Rett syndrome have provided clinical evidence for the efficacy of IGF-1, 107 thus increasing the interest in this compound and suggesting a broader application in other monogenic forms of autism spectrum disorder.
Several caveats need to be considered when evaluating the potential of translating preclinical findings into therapeutics. In fact, even clinical trials based on robust preclinical evidence have failed to provide clinical efficacy in humans and have therefore been terminated. 103 Yet, rigorous basic studies and drug testing in increasingly sophisticated animal models represent the most promising resource for the discovery of novel therapeutics. In particular, genetically modified rat models are evolving as a new model for autism spectrum disorder and autism-related syndromes including Phelan-McDermid syndrome, and they will provide the research community with a powerful tool not only for neurobiological and behavioral studies, but also for boosting drug discovery and development.
